Target Protein Degradation Market by 2030


Roots Analysis

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market. The USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following segments: Type of payment of licensing agreements • Upfront payments • Milestone payments Type of protein degrader • Degronimids • PROTACs • SARDs / SERDs • Specific BET and DUB inhibitors • Other protein degraders Therapeutic area • Neurodegenerative disorders • Oncological disorders • Other therapeutic areas Route of administration<br/>• Oral • Intravenous • Other routes Key geographical region • North America • Europe • Asia-Pacific The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain: Get detailed Analysis: Target Protein Degradation Market is projected to be over USD 3.6 billion by 2030 Key Players • Arvinas • Captor Therapeutics • Celgene • Genetech • Kymera Therapeutics • Mission Therapeutics • Progenra • Radius Health<br/>• Sanofi Genzyme • Zenopharm Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Current Market Landscape
  5. Company Profiles
  6. Clinical Trial Analysis
  7. KOL Analysis
  8. Publication Analysis
  9. Funding and Investment Analysis
  10. Partnerships and Collaborations
  11. Market Sizing and Opportunity Analysis
  12. Executive Insights
  13. Concluding Remarks
  14. Appendix 1: Tabulated Data
  15. Appendix 2: List of Companies and Organizations Get Customized Report:


PopularIn orderChat mode

No replies yet

Be the first one to reply to wilsonstella522

Joined discussion